Skip to main content

Table 2 Statistical comparison of the post-treatment parameters in glycemic improved patients versus glycemic non-improved patients

From: Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

  Glycemic non-improved
Patients (no = 53)
Glycemic improved
Patients (no = 32)
P value
Hemoglobin (g/dL)a 12.25 ± 1.44 12.57 ± 1.23 0.289
Leukocytes (× 103/μL cells)a 6.98 ± 1.72 6.58 ± 2.03 0.337
Platelets (× 103/μL cells)a 228.9 ± 51.77 217.31 ± 47.82 0.307
Albumin (g/dL)a 4.28 ± 0.39 4.31 ± 0.37 0.664
Bilirubin, total (mg/dL)a 0.67 ± 0.16 0.67 ± 0.19 0.848
INRa 1.07 ± 0.06 1.07 ± 0.09 0.992
AST (IU/L)a 22.38 ± 7.83 24.53 ± 8.27 0.232
ALT (IU/L)a 23.87 ± 9.43 24.22 ± 7.98 0.861
Creatinine (mg/dL)a 0.93 ± 0.18 0.88 ± 0.15 0.181
HbA1c (%)a 7.91 ± 0.79 6.50 ± 0.72 < 0.001
AFP (ng/mL)a 6.43 ± 4.09 6.56 ± 5.94 0.906
FIB-4b scorea 1.38 ± 0.47 1.17 ± 0.44 0.039
  1. aMean ± SD. Glycemic improved group: ≥ 1% reduction of baseline HbA1c levels at SVR. Non-glycemic improved group: < 1% reduction of baseline HbA1c levels at SVR
  2. AFP Alpha-fetoprotein, ALT Alanine transaminase, AST Aspartate transaminase, bFIB-4 score = [age 3AST]/[platelets 3 ALT1/2], INR international normalized ratio, HbA1c glycated hemoglobin